Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Renity Pharma AB
AB
Active
Org 5594796137
Kanalvägen 61, 191 34
Sollentuna
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2024 · 2 years old
1-4 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Renity Pharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
SEK millions
No figures reported for this period.
EBITDA
SEK millions
0M
0M
0M
-1M
-1M
2024: 0M
0M
2024
Income statement
SEK thousands
Item
2024
Gross profit
—
Staff expenses
—
EBITDA
−59
Depreciation & amort.
—
EBIT
−59
Net financials
—
Profit before tax
−59
Tax
—
Net profit
−59
Balance sheet
SEK thousands
Item
2024
Total assets
32
Equity
−34
Long-term debt
—
Short-term debt
66
Total debt
66
Financial ratios
5-year trend
EBITDA margin (of gross profit)
<−999 %
This company
2024
2024
Equity ratio
−107,9 %
This company
38,2 %
Market median
This company
Market median
382% below market
2024
2024
Return on equity
—
This company
18,4 %
Market median
This company
Market median
2024
2024
Net profit margin (of gross profit)
<−999 %
This company
2024
2024
Asset turnover (of gross profit)
0,00×
This company
2024
2024
Debt / equity
—
This company
0,62×
Market median
This company
Market median
2024
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-04-15 – 2024-12-31
View
PDF
More on Renity Pharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
